ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO ACHIEVE LONG-TERM REMISSION. UPDATED RESULTS OF A PHASE II, MULTICENTER, PROSPECTIVE STUDY BY GIMEMA GROUP (THE ESTIT STUDY)
HAEMATOLOGICA（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要